دورية أكاديمية
A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf
| العنوان: | A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf |
|---|---|
| المؤلفون: | James D. Chalmers, Abhya Gupta, Sanjay H. Chotirmall, April Armstrong, Peter Eickholz, Naoki Hasegawa, Pamela J. McShane, Anne E. O'Donnell, Michal Shteinberg, Henrik Watz, Anastasia Eleftheraki, Claudia Diefenbach, Wiebke Sauter |
| المصدر: | ERJ Open Research, Vol 9, Iss 3 (2023) |
| بيانات النشر: | European Respiratory Society, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | Medicine |
| الوصف: | New therapies are needed to prevent exacerbations, improve quality of life and slow disease progression in bronchiectasis. Inhibition of cathepsin C (CatC) activity has the potential to decrease activation of neutrophil-derived serine proteases in patients with bronchiectasis, thereby reducing airway inflammation, improving symptoms, reducing exacerbations and preventing further airway damage. Here we present the design of a phase 2 trial (Airleaf™; NCT05238675) assessing the efficacy and safety of a novel CatC inhibitor, BI 1291583, in adult patients with bronchiectasis. This multinational, randomised, double-blind, placebo-controlled, parallel-group, dose-finding study has a screening period of at least 6 weeks, a treatment period of 24–48 weeks and a follow-up period of 4 weeks. ∼240 adults with bronchiectasis of multiple aetiologies will be randomised to placebo once daily, or BI 1291583 1 mg once daily, 2.5 mg once daily or 5 mg once daily in a 2:1:1:2 ratio, stratified by Pseudomonas aeruginosa infection and maintenance use of macrolides. The primary efficacy objective is to evaluate the dose–response relationship for the three oral doses of BI 1291583 versus placebo on time to first pulmonary exacerbation up to Week 48 (the primary end-point). Efficacy will be assessed using exacerbations, patient-reported outcomes, measures of symptoms, sputum neutrophil elastase activity and pulmonary function testing. Safety assessment will include adverse event reporting, physical examination, monitoring of vital signs, safety laboratory parameters, 12-lead electrocardiogram, and periodontal and dermatological assessments. If efficacy and safety are demonstrated, results will support further investigation of BI 1291583 in phase 3 trials. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2312-0541 23120541 82442584 |
| Relation: | http://openres.ersjournals.com/content/9/3/00633-2022.full; https://doaj.org/toc/2312-0541 |
| DOI: | 10.1183/23120541.00633-2022 |
| URL الوصول: | https://doaj.org/article/f31442a25f82442584c4258c2b47a8fe |
| رقم الأكسشن: | edsdoj.f31442a25f82442584c4258c2b47a8fe |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 23120541 82442584 |
|---|---|
| DOI: | 10.1183/23120541.00633-2022 |